Oxime ethers as IIb/IIa antagonists
    1.
    发明授权
    Oxime ethers as IIb/IIa antagonists 失效
    肟醚作为IIb / IIa拮抗剂

    公开(公告)号:US06348504B1

    公开(公告)日:2002-02-19

    申请号:US09282037

    申请日:1999-03-30

    IPC分类号: A61K3133

    摘要: This invention relates generally to oxime ethers which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

    摘要翻译: 本发明一般涉及可用作血小板糖蛋白IIb / IIIa纤维蛋白原受体复合物的拮抗剂的肟醚,含有这些化合物的药物组合物,制备这些化合物的方法,以及使用这些化合物抑制血小板聚集的方法, 作为血栓溶解剂,和/或用于治疗血栓栓塞障碍。

    Substituted lactams as inhibitors of Aβ protein production
    6.
    发明授权
    Substituted lactams as inhibitors of Aβ protein production 有权
    取代的内酰胺作为Abeta蛋白质生产的抑制剂

    公开(公告)号:US07655647B2

    公开(公告)日:2010-02-02

    申请号:US12388944

    申请日:2009-02-19

    摘要: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及式(I)的新型内酰胺:具有药物和生物影响性质,其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ肽的产生,从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病,例如阿尔茨海默病和唐氏综合征。

    Substituted lactams as inhibitors of abeta protein production
    9.
    发明申请
    Substituted lactams as inhibitors of abeta protein production 失效
    取代的内酰胺作为abeta蛋白质生产的抑制剂

    公开(公告)号:US20080221087A1

    公开(公告)日:2008-09-11

    申请号:US11788708

    申请日:2007-04-19

    摘要: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及式(I)的新型内酰胺:具有药物和生物影响性质,其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ肽的产生,从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病,例如阿尔茨海默病和唐氏综合征。

    SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION
    10.
    发明申请
    SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION 失效
    作为ABETA蛋白生产抑制剂的苯甲酰胺

    公开(公告)号:US20080207602A1

    公开(公告)日:2008-08-28

    申请号:US12061227

    申请日:2008-04-02

    申请人: Richard E. Olson

    发明人: Richard E. Olson

    摘要: This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及具有式(I)的新型内酰胺:其药物组合物及其使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ肽的产生,从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病,例如阿尔茨海默病和唐氏综合征。